No Detail Found!

Irbesartan; An Antihypertensive Drug Reduces LDL-cholesterol in Diet Induced Hyperlipidemic Rabbits.

Author(s)
Sabeen Shakir Department of Pharmacology Rawal Institute of Health Sciences, Islamabad, Pakistan
Akbar Waheed Department of Pharmacology Islamic International Medical College Riphah International University, Islamabad, Pakistan
Noureen Hafeez Department of Forensic Medicine Rawal Institute of Health Sciences, Islamabad, Pakistan
Abstract
Objective: This study on animal model was designed to explore the LDL-Cholesterol lowering effect of an antihypertensive drug Irbesartan. Study Design: Randomised controlled experimental study. Place and Duration of Study: The study was conducted in the animal house of National Institute of Health (NIH), Islamabad. Biochemical analysis of rabbit's serum was carried out in the department of chemical pathology, Army Medical College, Rawalpindi from February 2013 to June 2013. Materials and Methods: Eighteen rabbits were divided into three groups (group A, group B and group C) of six rabbits each. Group one was labelled as normal control. The other two groups (B and C) were made hyperlipidemic by feeding them with high cholesterol diet. Of these, group B was taken as hyperlipidemic control and group C as treatment group. Serum LDL levels were estimated at three different occasions i.e. baseline, after giving high cholesterol diet to hyperlipidemic groups and after 30 days of giving irbesartan to treatment group. Results: Serum analysis for the estimation of LDL-Cholesterol of all the groups was done and their means were calculated and compared with the base line values using SPSS Version 20. Irbesartan treated group showed a marked reduction in serum LDL cholesterol in comparison with the hyperlipidemic control group. Conclusion: It is concluded that Irbesartan an antihypertensive agent, has also the ability to markedly reduce raised serum LDL cholesterol levels.
Publication Details
Page(s) 94-98
DOI DOI not available
Published Journal: Journal of Islamic International Medical College, Volume: 11, Issue: 3, Year: 2016

Request the full text from PASTIC

References
LimSS,VosT,FlaxmanAD,DanaeiG,ShibuyaK,Adair Rohani H, 2012.a systematic analysis for the Global Burden of Disease Study 2010, 380 2224 -60
StellaMG,KyvelouGP,VyssoulisEA,KarpanouDN,AdamopoulosAI,ZervoudakiPG, 2006.Effects of antihypertensive treatment withangiotensin ii receptor blockers on lipid profile: an open multi-drug comparison trial,Hellenic J Cardiol 47 21 -8
YuQ,LarsonDF,SlaybackD,LundeenTF,BaxterJH,WatsonRR, 2004.Characterization of high-salt and high-fat diets on cardiac and vascular function in mice,Cardiovascc. Toxicol 4 37 -46
PohanK., 2006.Lipid-lowering drugs,Cell Mol Life Sci 63 1165 -78
GhibaudiL,CookJ,FrarleyC,Van HeekM., 2002.Fat inktake affects adiposity comorbid factors, and energy metabolism of Sprague-Dawley rats,Obes Res 10 956 -63
ColpoA. LDL, 2005.Cholesterol: Bad cholesterol, or bad science?,JPANDS 10 83 -9
LarosaJC,HeJ,VupputuriS, 1999.Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials,JAMA 282 2340 -6
FadicR,JohnsDR,BealMF,HowellN, 1997.free radicals in neurodegerative disease, 19 537 -5
SeverP, 1997.Candesartan cilexetil: A new, long-acting, effective angiotensin II type 1 receptor blocker,J Hum Hypertens 11 91 -5
BrunnerHR, 1997.The new angiotensin ii receptor antagonist, irbesartan: pharmacokinetic and pharmacodynamic considerations,Am J Hypertens 10 311 -7
Marino,MariaR,VachharajaniNN, 2002.Pharmacokinetics of irbesartan are not altered in special populations,J CardiovascPharmacol 40 112 -22
TronquetC,MandrayM,MasseD,MiscoriaG,BergerY., 1996.Excretion and metabolism following single oral a d m i n i s t ra t i o n ( 1 0 m g / k g ) o f i r b e s a r ta n t o Macacafascicularis monkeys,CA ISSX 10 321 -
VachharajaniNNE,ShyuCW,SmithAR,GreeneSD, 1998.The effects of age and gender on the pharmacokinetics of irbesartan,Br J ClinPharmacol 46 611 -3
RiveiroA,MosqueraA,AlonsoM,CalvoC, 2002.Angiotensin II type 1 receptor blocker irbesartan ameliorates vascular function in spontaneously hypertensive rats regardless ofoestrogen status,J Hypertens 20 1365 -72
WaeberB,BrunnerHR, 2003.Angiotensin 11-antagonists: A new class of antihypertensive agent,Br J Clinprac 50 265 -8
BarrerasA,TurnerGC, 2003.Angiotensin II receptor blockers,BaylUniv Med 16 123 -6
RongX,LiY,ZhaoM,KusakabeT,TomitaT,MurrayM, 2010.Irbesartan treatment upregulates hepatic expression of PPAR alpha and its target genes in obese koletsky rats: a link to amelioration of hypertriglyceridemia,Br J Pharmacol 160 1796 -807
DerosaG,FogariE,AngeloAD,CircirotAFG,SalvadeoSAT,RagonesiPD, 2007.Metabolic effects of telmisartan and irbesartan in type 2 diabetic patients with metabolic syndrome treated with rosiglitazone,J Clin Phar Ther 32 261 -8
YutingC,RongliangZ,ZhongjianiJ, 1990.Flavanoids as superoxide scavengers and as antioxidants,Free Rad Biol Med 9 19 -
PadillaE,SanzM,GanadoP,TejerinaTY, 2002.Effects of irbesartan and losartan in cholesterol-fed rabbits,Clin Invest Arterioscl 14 230 -8
BimenyaSG,KasoloJ,OkwiLA,OthienoI,OchiengJ,KaluleB, 2010.Determination of LDL-cholesterol: direct measurement by homogenous assay versus Friedewald calculation among Makerere University undergraduate fasting student,Int J Biol Chem 4 464 -70
MaxwellKN,SoccioRE,DuncanEM,SehayekE,Jl, 2003.Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice,Lipid Res 44 2109 -19
ShimamuraM,NakagamiH,MoritaniT,NakagamiF,OsakoKM, 2011.Irbesartan improves endothelial dysfunction, abnormal lipid profile, proteinuria and liver dysfunction in Zucker diabetic fatty rats independent of glucose and insulin levels,Experimental and Therapeutic Medicine 2 957 -61
GiordanoM,MatsudaM,SandersL,CanessaML,DeFronzo RA, 1995.Effects of angiotensin-converting enzyme inhibitors, Ca2+ channel antagonists, and α-adrenergic blockers on glucose and lipid metabolism in NIDDM patients with hypertension,Diabetes 44 665 -71
HashimotoM,KagotaS,KubotaY,KatakuraM,EnkhjargalB,GamohS, 2007.Effect of amlodipine, a calcium channel antagonist, on cholesterol levels in the cerebral cortex and hippocampus of obese and hypertensive SHR,Clin Exp Pharmacol 34 35 -6
KirkKJ, 1999.Angiotensin-II Receptor Antagonists: Their Place in Therapy,Am Fam Physician 59 3140 -8
SanzM,GanadoP,TejerinaT, 2002.Two angiotensin AT1 receptor antagonists, irbesartan and losartan, effects in cholesterolfed rabbits,Eur J Pharmacol 442 99 -106
MarkhamA,GoaKL.,Valsartan, 1997.A review of its pharmacology and therapeutic use in essential hypertension,Drugs 54 299 -311
MiwaK,MurakamH,MasakiK,IwasakiM,YoshimuraM.,JHypertens, 1998.In vitro hepatic metabolism of candesartan to its inactive metabolite, CV-15959, 16 128 -
OparilS,WilliamsD,ChrysantSG, 2001.Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension,J Clin Hypertens 3 283 -91
0

Citations

0

Downloads

33

Views